0639 GMT - Alibaba Health Information Technology's and JD Health's software-as-a-service businesses aren't likely to be hurt by artificial intelligence, says Morningstar's Kai Wang in a note. Both stocks have lost around 10% in market valuation since news of AI possibly supplanting traditional software and services, the analyst says. While both companies offer software-as-a-service such as telemedicine, licensed doctors are still required to make diagnoses for patient queries, he says. "We believe investors are conflating risks to software with health platforms and that AI can eventually perform the same tasks as diagnosing illnesses," he says. "We don't see this occurring from a regulatory perspective, as an incorrect diagnosis would significantly erode public trust in a nascent industry." (megan.cheah@wsj.com)
(END) Dow Jones Newswires
February 19, 2026 01:39 ET (06:39 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.